Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $41.33.
Several brokerages recently commented on HRMY. UBS Group initiated coverage on Harmony Biosciences in a research note on Tuesday, September 10th. They issued a “buy” rating and a $56.00 price target for the company. Citigroup assumed coverage on Harmony Biosciences in a research report on Friday, June 21st. They issued a “buy” rating and a $48.00 price target on the stock. Finally, Needham & Company LLC reissued a “buy” rating and set a $52.00 price objective on shares of Harmony Biosciences in a research report on Thursday, September 12th.
Read Our Latest Report on HRMY
Harmony Biosciences Price Performance
Harmony Biosciences (NASDAQ:HRMY – Get Free Report) last announced its earnings results on Tuesday, August 6th. The company reported $0.20 EPS for the quarter, topping the consensus estimate of ($0.04) by $0.24. The company had revenue of $172.80 million during the quarter, compared to analysts’ expectations of $172.53 million. Harmony Biosciences had a net margin of 17.53% and a return on equity of 22.97%. The business’s revenue for the quarter was up 28.8% on a year-over-year basis. During the same period last year, the company posted $0.56 earnings per share. Equities analysts anticipate that Harmony Biosciences will post 2.19 EPS for the current year.
Hedge Funds Weigh In On Harmony Biosciences
A number of hedge funds have recently made changes to their positions in the business. TFO Wealth Partners LLC lifted its holdings in shares of Harmony Biosciences by 98,700.0% during the fourth quarter. TFO Wealth Partners LLC now owns 988 shares of the company’s stock valued at $32,000 after acquiring an additional 987 shares during the period. Quadrant Capital Group LLC boosted its position in Harmony Biosciences by 47.5% in the fourth quarter. Quadrant Capital Group LLC now owns 1,022 shares of the company’s stock valued at $33,000 after buying an additional 329 shares in the last quarter. nVerses Capital LLC bought a new stake in Harmony Biosciences during the second quarter worth about $36,000. Quarry LP acquired a new stake in shares of Harmony Biosciences during the second quarter worth approximately $62,000. Finally, Headlands Technologies LLC raised its stake in shares of Harmony Biosciences by 1,608.1% in the second quarter. Headlands Technologies LLC now owns 2,545 shares of the company’s stock valued at $77,000 after acquiring an additional 2,396 shares during the last quarter. Institutional investors and hedge funds own 86.23% of the company’s stock.
About Harmony Biosciences
Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Featured Stories
- Five stocks we like better than Harmony Biosciences
- Financial Services Stocks Investing
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- How to Invest in the Best Canadian Stocks
- MarketBeat Week in Review – 9/16 – 9/20
- Stock Splits, Do They Really Impact Investors?
- Don’t Miss These 3 Retail Stocks for Fall Gains
Receive News & Ratings for Harmony Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harmony Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.